Allogeneic hematopoietic cell transplantation (alloHCT) is a well-established therapy for different lifethreatening hematologic malignancies. The use of alloHCT is constantly increasing, with nearly 20 000 transplantations reported to the European Society for Blood and Marrow Transplantation (EBMT) per year. However, this treatment is limited by high morbidity and mortality, mainly related to relapse, infection, graft-versus-host disease (GvHD), and conditioning-related toxicity. Therefore, overall survival (OS) and GvHD-free, relapse-free survival (GRFS) after alloHCT, remain low, around 60% and 30% at one year. Over ...

GO TO STUDY

Although the optimal treatment strategy in oesophageal (food pipe) cancer has been the subject of research for several decades, overall outcomes are very poor, with a 5-year survival of 15%. In the UK there are 9100 new cases of oesophago-gastric cancer diagnosed and approximately 7925 deaths every year (Cancer Research UK Oct 2019). Oesophageal cancer is a strategic priority for CRUK and a serious health problem world-wide. Pre-surgery treatment consists of chemotherapy or chemoradiation, but the optimal treatment is unknown. ...

GO TO STUDY

This placebo-controlled, double-blind, randomized, Phase 3 study is being conducted in adult participants with high-risk atherosclerotic cardiovascular disease (ASCVD) who are not adequately controlled by their maximally tolerated lipid-modifying therapy, to assess the impact of the obicetrapib 10 mg + ezetimibe 10 mg FDC therapy on coronary plaque and inflammation characteristics, evaluated using cardiovascular computed tomography angiography (CCTA). Approximately 300 eligible participants will be randomized in a 1:1 ratio, respectively, to the following treatment groups: • Obicetrapib 10 mg + ezetimibe 10 ...

GO TO STUDY

Peripheral artery disease (PAD) is a reduction of blood flow in the legs due to the narrowing or blockage of arteries. The prevalence of vascular calcification in patients with PAD hinders the outcome of endovascular treatments due to increased stiffness of the vessel wall. Treatment failure is especially high in patients with chronic limb-threatening ischemia (CLTI), the most advanced type of PAD, characterized by rest pain and tissue loss. These patients are at a high risk of limb amputation and ...

GO TO STUDY

The MANTRA trial is an open label, non-blinded, multicentre non-inferiority RCT with an internal pilot comparing the safety and effectiveness of three different surgical prophylaxis antibiotic regimens following surgery for mandible fractures. This is a multicentre trial in secondary care, involving multiple NHS OMFS units treating mandible fractures. We aim to set-up >25 sites over a 3-year trial period. We have provisional participation agreement with >50 sites and written commitment from the only UK specialist association (BAOMS) to promote, support ...

GO TO STUDY

This is a multicenter, open-label, active control extension study to assess the long-term safety and efficacy of tegoprubart compared with tacrolimus in the preservation of allograft function after kidney transplantation. To be eligible for participation in this study, participants must have completed a designated Parent study. Qualification for this open-label extension (OLE) study will be specified in the Parent study Protocol. Participants who discontinue treatment early or discontinue from the Parent study are not eligible for this OLE study AT-1501-K209. Prospective participants ...

GO TO STUDY

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stage II to IIIB (N2) NSCLC for Participants not Achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum based Doublet Chemotherapy Followed by Surgery.

GO TO STUDY

Each year in the NHS more than 250,000 high risk patients contemplate major surgery. These patients are older and usually have chronic disease. One in three high risk patients who choose surgery will experience will experience medical complications leading to long-term decline in health and quality of life. Awareness of these long term risks is poor amongst both doctors and patient. Consequently, many high-risk patients do not receive the information they need to make an informed decision about surgery. Shared ...

GO TO STUDY

The overall aim is: Part 1: To determine the efficacy of Pola-Glofit as bridging treatment to CAR-T cell therapy in patients with relapsed or refractory large B cell lymphomas. Part 2: To determine the efficacy of Pola-Glofit in patients with relapsed or refractory large B cell lymphomas who have failed to achieve complete metabolic response,or progressed after CAR-T cell therapy. The primary endpoints are: Part 1: Overall response rate (ORR) (Complete Metabolic Response (CMR) and Partial Metabolic Response (PMR)) after Pola-Glofit but prior to ...

GO TO STUDY

Study type Multicentre,non-blinded,feasibility randomised controlled trial Aim Feasibility study to assess feasibility of progressing to a full scale trial to evaluate strategies for platelet transfusion in participants with thrombocytopaenia and cancer associated thrombus (CAT) receiving anticoagulation Primary objective To determine the feasibility of designing and recruiting to a full RCT of management in participants with acute cancer-associated thrombosis (developed within 14 days) and thrombocytopaenia. Secondary objectives To determine: • Additional feasibility measures,such as recruitment rate,reasons for non participation in eligible participants and withdrawal rates and participation barriers ...

GO TO STUDY